KKR Stock Plunges 6.37% Amid Share Sale Plans

On April 4, 2025, KKR's stock price dropped by 6.37% in pre-market trading, signaling a significant shift in investor sentiment.

KKR recently announced plans to sell up to $300 million worth of shares in J.B. Chemicals & Pharmaceuticals Limited, which could potentially impact its financial position and investor confidence.

HSBC downgraded KKR's stock rating from "buy" to "hold," while also increasing their price target from $153.00 to $173.00. This move reflects a cautious outlook on the company's near-term prospects.

KKR's stock has underperformed compared to its competitors, which may be attributed to broader market trends and specific company developments.

Despite recent challenges, KKR remains committed to driving sustainable global solutions, as evidenced by its alignment with Novo Holdings in supporting Sylvan's progress.